Clovis Oncology (NASDAQ:CLVS) insider Patrick J. Mahaffy purchased 50,000 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was acquired at an average price of $5.59 per share, with a total value of $279,500.00. Following the completion of the transaction, the insider now owns 919,187 shares in the company, valued at approximately $5,138,255.33. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of CLVS traded up $0.35 during trading hours on Monday, hitting $5.95. 67,345 shares of the stock were exchanged, compared to its average volume of 4,697,737. Clovis Oncology has a fifty-two week low of $4.98 and a fifty-two week high of $37.27. The company has a debt-to-equity ratio of 8.04, a current ratio of 3.57 and a quick ratio of 3.32. The business has a 50-day moving average of $10.96 and a 200-day moving average of $18.78. The firm has a market capitalization of $306.10 million, a P/E ratio of -0.84 and a beta of 1.86.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($2.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.70) by ($0.57). Clovis Oncology had a negative return on equity of 372.68% and a negative net margin of 332.18%. The firm had revenue of $32.98 million for the quarter, compared to analyst estimates of $34.92 million. During the same quarter last year, the company earned ($1.94) earnings per share. The company’s quarterly revenue was up 38.8% compared to the same quarter last year. As a group, analysts forecast that Clovis Oncology will post -7.44 earnings per share for the current fiscal year.

CLVS has been the subject of several recent research reports. Gabelli restated a “buy” rating on shares of Clovis Oncology in a research report on Friday, August 2nd. Piper Jaffray Companies reiterated a “neutral” rating on shares of Clovis Oncology in a research report on Thursday, August 1st. Barclays set a $36.00 price objective on shares of Clovis Oncology and gave the stock a “buy” rating in a research report on Friday, August 2nd. ValuEngine upgraded shares of Clovis Oncology from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Royal Bank of Canada set a $26.00 price objective on shares of Clovis Oncology and gave the stock a “buy” rating in a research report on Friday, August 2nd. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $25.09.

A number of large investors have recently bought and sold shares of CLVS. Ropes Wealth Advisors LLC acquired a new stake in Clovis Oncology in the second quarter worth $27,000. Pearl River Capital LLC acquired a new stake in Clovis Oncology in the first quarter worth $40,000. Aperio Group LLC acquired a new stake in Clovis Oncology in the second quarter worth $48,000. Quantamental Technologies LLC acquired a new stake in Clovis Oncology in the second quarter worth $53,000. Finally, Bank of Montreal Can grew its holdings in Clovis Oncology by 55.8% in the second quarter. Bank of Montreal Can now owns 9,652 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 3,457 shares during the period. Institutional investors and hedge funds own 92.13% of the company’s stock.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

See Also: The role of implied volatility with call option volume

Insider Buying and Selling by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.